Ascendis Pharma AS (BSP:A1SN34)
R$ 48.84 0 (0%) Market Cap: 2.92 Bil Enterprise Value: 5.48 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Ascendis Pharma A/S at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 04:20PM GMT
Release Date Price: R$30.18
Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Okay. We'll continue with our next session. I'm Paul Choi, and I cover the mid cap biotechnology sector here at Goldman Sachs. We're very pleased to have Ascendis here in our session here. Before we begin, to my left is CEO, Jan Mikkelsen; and to my far left, CFO, Scott Smith. I think Tim is going to read some forward language here before we begin the Q&A, but we'll let Tim go here.

Timothy J. Lee;S;Senior Director of IR
Ascendis Pharma A

/-

Comments during this discussion. Actual results made materially from those expressed or implied, and you should not place undue reliance on these statements. For information concerning the factors that can cause actual results to differ materially, please see the Risk Factors section of our most recent Annual Report on Form 20-F. And with that, let me turn it back to Paul.

Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Thanks, Tim. So maybe what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot